DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Phase II Study of TPA Plus Dexamethasone & CMT in Hematologic Malignancies

Information source: Rutgers, The State University of New Jersey
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Leukemia

Intervention: 12-O-tetradecanoylphorbol-13-acetate (Drug); Dexamethasone (Drug); Choline magnesium trisalicylate (Drug)

Phase: Phase 2

Status: Terminated

Sponsored by: Rutgers, The State University of New Jersey

Official(s) and/or principal investigator(s):
Roger Strair, MD, PhD, Principal Investigator, Affiliation: Rutgers Cancer Institute of New Jersey


This phase II trial is studying the side effects and how well giving tetradecanoylphorbol acetate together with dexamethasone and choline magnesium trisalicylate works in treating patients with relapsed or refractory acute myeloid leukemia.

Clinical Details

Official title: A Phase II Study of 12-O-tetradecanoylphorbol-13-acetate (TPA) Plus Dexamethasone & Choline Magnesium Trisalicylate in the Treatment of Patients With Relapsed/Refractory Acute Myelogenous Leukemia

Study design: Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome:

Response Rate > 20% for 12-O-tetradecanoylphorbol-13- Acetate (TPA)+ Dexamethasone + Choline Magnesium Trisalicylate(Trilisate)

Grade 3 and 4 Non-hematologic Treatment-related Toxicity Rates < 25%

Secondary outcome: Effects of Treatment on Immunophenotype, Signaling Profile, and Nuclear NF-kB Expression


Minimum age: 18 Years. Maximum age: N/A. Gender(s): Both.


Inclusion Criteria

- Must have a histologically documented relapsed/refractory AML for which there is no

standard therapy that has been demonstrated to have curative or palliative potential.

- ECOG performance status of 0-2.

- Must be 18 years or older.

- Estimated life expectancy > 1 month.

- Laboratory data:

- total bilirubin ≤ 1. 5 x upper limit of normal unless due to Gilbert's syndrome

- serum creatinine ≤ 2. 0 mg/dl

- AST ≤ 3. 0 x upper limit of normal

- Cardiac ejection fraction > 40%

- FEV1. 0 > 50% predicted

- Prior therapy: > 3 weeks since chemotherapy, biological therapy or radiation;

anticipated maximum hematological improvement since last dose of chemotherapy. (Concurrent hydroxyurea administration will be allowed to control WBC count, platelet count, or symptoms).

- No active infections.

- Negative pregnancy test for women of childbearing potential.

- No uncontrolled psychiatric illness or medical illness that the principal

investigator feels will compromise the patient's tolerance of the study medication.

- Must provide informed consent.

Exclusion Criteria

- Patients with an allergy to proton pump inhibitors, required for GI prophylaxis; or

salicylates are excluded.

- Pregnant or lactating women

- Age <18 years. Because no dosing or adverse event data are currently available on the

use of TPA alone or in combination with dexamethasone in patients < 18 years of age, children are excluded from this study but will be eligible for future pediatric Phase II combination trials.

- The effects of TPA on the developing human fetus are unknown. For this reason, women

of childbearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation and for 10 weeks after. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately. Should the female partner of a participant in this study become pregnant or suspect she is pregnant during this study, the PI of this study will be available to provide advice about further medical/obstetric care/referral for the female partner.

- Patients with active CNS involvement (documented by radiographic lesions and/or

malignant cells in the CSF) will be excluded from this clinical trial because of their poor prognosis and because they often develop progressive neurologic dysfunction that would confound the evaluation of neurologic and other adverse events.

- Patients with treatment of any other investigational drug within the last 30 days

prior to entering the study.

Locations and Contacts

Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey 08903, United States
Additional Information

Clinical trial summary from the National Cancer Institute's PDQ® database

Starting date: March 2011
Last updated: June 19, 2015

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017